<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Intercure — News on 6ix</title>
<link>https://6ix.com/company/intercure</link>
<description>Latest news and press releases for Intercure on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 03 Mar 2026 21:46:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/intercure" rel="self" type="application/rss+xml" />
<item>
<title>InterCure Receives Nasdaq Notification Regarding Minimum Bid Requirement</title>
<link>https://6ix.com/company/intercure/news/intercure-receives-nasdaq-notification-regarding-minimum-bid-requirement-31</link>
<guid isPermaLink="true">https://6ix.com/company/intercure/news/intercure-receives-nasdaq-notification-regarding-minimum-bid-requirement-31</guid>
<pubDate>Tue, 03 Mar 2026 21:46:00 GMT</pubDate>
<description>NEW YORK and HERZLIYA, Israel, March 03, 2026 (GLOBE NEWSWIRE) -- InterCure Ltd. (Nasdaq: INCR) (TASE: INCR) (“InterCure” or the “Company”) today announced that on February 25, 2026 the Company received a written notice (the “Notice”) from the Nasdaq Stock Market LLC indicating that the Company was not in compliance with Nasdaq Listing Rule 5450(a)(2), as the Company’s closing bid price for its ordinary shares, or Ordinary Shares, was below $1.00 per share for the last 30 consecutive business da</description>
</item>
<item>
<title>InterCure Announces Preliminary Estimated 2025 Revenue of NIS 265 Million, Positive Adjusted EBITDA and Cash of NIS 43 Million</title>
<link>https://6ix.com/company/intercure/news/intercure-announces-preliminary-estimated-2025-revenue-of-nis-265-million-positive-adjusted-ebitda-and-cash-of-nis-43-million</link>
<guid isPermaLink="true">https://6ix.com/company/intercure/news/intercure-announces-preliminary-estimated-2025-revenue-of-nis-265-million-positive-adjusted-ebitda-and-cash-of-nis-43-million</guid>
<pubDate>Thu, 19 Feb 2026 12:00:00 GMT</pubDate>
<description>InterCure reports preliminary estimated revenue of NIS 265 million for 2025 and positive Adjusted EBITDA, marking its twelfth consecutive half-year of positive Adjusted EBITDA. Revenue for 2025 represents an increase of approximately 11% compared to 2024, while revenue for the second half of 2025 is nearly 20% higher than the corresponding period in the prior year. During the second half of 2025, the Company generated its first significant revenues from the German market. NEW YORK and HERZLIYA,</description>
</item>
<item>
<title>InterCure Announces Preliminary Estimated 2025 Revenue of NIS 265 Million, Positive Adjusted EBITDA and Cash¹ of NIS 43 Million</title>
<link>https://6ix.com/company/intercure/news/intercure-announces-preliminary-estimated-2025-revenue-of-nis-265-million-positive-adjusted-ebitda-and-cash-of-nis-43-million-1</link>
<guid isPermaLink="true">https://6ix.com/company/intercure/news/intercure-announces-preliminary-estimated-2025-revenue-of-nis-265-million-positive-adjusted-ebitda-and-cash-of-nis-43-million-1</guid>
<pubDate>Thu, 19 Feb 2026 12:00:00 GMT</pubDate>
<description>InterCure reports preliminary estimated revenue of NIS 265 million for 2025 and positive Adjusted EBITDA2, marking its twelfth consecutive half-year of positive Adjusted EBITDA. Revenue for 2025 represents an increase of approximately 11% compared to 2024, while revenue for the second half of 2025 is nearly 20% higher than the corresponding period in the prior year. During the second half of 2025, the Company generated its first significant revenues from the German market. NEW YORK and HERZLIYA,</description>
</item>
<item>
<title>InterCure and Cannasoul Sign Strategic Investment and Collaboration Agreements to Advance Cannabis Science and Pharmaceutical Innovation</title>
<link>https://6ix.com/company/intercure/news/intercure-cannasoul-sign-strategic-investment-133000283</link>
<guid isPermaLink="true">https://6ix.com/company/intercure/news/intercure-cannasoul-sign-strategic-investment-133000283</guid>
<pubDate>Mon, 03 Nov 2025 13:30:00 GMT</pubDate>
<description>Agreements formalize research partnership combining InterCure’s global pharmaceutical platform with Cannasoul’s world-class analytics and scientific innovation Collaboration comes amidst reports that the Trump administration is exploring cannabis rescheduling, expected to create unprecedented opportunities in the U.S. for international operators like InterCure NEW YORK & HERZLIYA, Israel , Nov. 03, 2025 (GLOBE NEWSWIRE) -- InterCure Ltd. (Nasdaq: INCR / TASE: INCR) (“InterCure” or the “Company”)</description>
</item>
<item>
<title>InterCure Reports First Half 2025 Results with NIS 130 Million in Revenue and Positive Operating Cash Flow</title>
<link>https://6ix.com/company/intercure/news/intercure-reports-first-half-2025-134000509</link>
<guid isPermaLink="true">https://6ix.com/company/intercure/news/intercure-reports-first-half-2025-134000509</guid>
<pubDate>Wed, 08 Oct 2025 13:40:00 GMT</pubDate>
<description>The Company reports NIS 130 million in revenue and NIS 12 million in positive operating cash flow, demonstrating resilience and sustained profitability with its eleventh consecutive half of positive Adjusted EBITDA amidst ongoing recovery in Israel InterCure is encouraged by recent regulatory momentum in the U.S. and believes that it is well positioned to capitalize on evolving U.S. cannabis rescheduling, especially following its recent signing of an agreement to acquire ISHI NEW YORK and HERZLI</description>
</item>
<item>
<title>InterCure Announces Strategic Acquisition of ISHI, Unlocking Access to Premium U.S. Cannabis Technology and Brands</title>
<link>https://6ix.com/company/intercure/news/intercure-announces-strategic-acquisition-ishi-124800699</link>
<guid isPermaLink="true">https://6ix.com/company/intercure/news/intercure-announces-strategic-acquisition-ishi-124800699</guid>
<pubDate>Fri, 19 Sep 2025 12:48:00 GMT</pubDate>
<description>Acquisition of leading cannabis company marks major milestone in InterCure’s commercial expansion strategy, bringing access to premium American brands and state-of-the-art cultivation technologies Transaction comes as Trump administration confirms it is exploring cannabis rescheduling, creating unprecedented potential opportunities for international operators like InterCure InterCure encouraged by recent regulatory momentum and positioned to capitalize on evolving U.S. cannabis landscape NEW YOR</description>
</item>
<item>
<title>InterCure Announces FY2024 Results and Provides Q1 2025 Update: Revenue of NIS 239 Million and Adjusted EBITDA of NIS 24 Million, Strong Start to 2025</title>
<link>https://6ix.com/company/intercure/news/intercure-announces-fy2024-results-provides-200000072</link>
<guid isPermaLink="true">https://6ix.com/company/intercure/news/intercure-announces-fy2024-results-provides-200000072</guid>
<pubDate>Thu, 01 May 2025 20:00:00 GMT</pubDate>
<description>InterCure Ltd. (Nasdaq: INCR) (TASE: INCR) ("InterCure" or the "Company") today announced results for the full year ended December 31, 2024. All amounts are expressed in New Israeli Shekels (NIS), unless otherwise noted.</description>
</item>
</channel>
</rss>